heartburn drug Nexium and Roche's antiviral Valcyte.
These two drugs are pending final approval from the FDA.
Last month, Ranbaxy Chief Executive Arun Sawhney said he was "confident" that the company would be able to reap the benefits of these exclusive marketing opportunities.
He did not elaborate.
"I think the Diovan generic approval is definitely a validation of their comment that they will be able to launch Valcyte and Nexium as well," Nirmal Bang's Bohra said.